Litcius/Paper detail

Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of the OPT-BIRISK double-blinded, placebo-controlled randomized trial

Yi Li, Quanmin Jing, Bing Wang, Xiaozeng Wang, Jing Li, Shu-Bing Qiao, Shao‐Liang Chen, Dominick J. Angiolillo, Yaling Han

2020American Heart Journal19 citationsDOIOpen Access PDF

Topics & Concepts

MedicineClopidogrelAspirinAcute coronary syndromeInternal medicineCardiologyPlatelet aggregation inhibitorMyocardial infarctionAntiplatelet Therapy and Cardiovascular DiseasesAcute Myocardial Infarction ResearchCoronary Interventions and Diagnostics
Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of the OPT-BIRISK double-blinded, placebo-controlled randomized trial | Litcius